Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor.

Bioorganic & medicinal chemistry letters·2025
Same author

4-Phenylbutyric Acid Improves Gait Ability of UBAP1-Related Spastic Paraplegia Mouse Model: Therapeutic Potential for SPG80.

International journal of molecular sciences·2025
Same author

Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.

Bioorganic & medicinal chemistry letters·2024
Same author

A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.

RSC medicinal chemistry·2023
Same author

Discovery of a Novel Class of ERRα Agonists.

ACS medicinal chemistry letters·2021
Same author

Loss of the fragile X mental retardation protein causes aberrant differentiation in human neural progenitor cells.

Scientific reports·2018

Related Experiment Video

Updated: Apr 30, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

33.7K

Inhibiting RORγt/Th17 axis for autoimmune disorders.

Fujio Isono1, Saori Fujita-Sato2, Shuichiro Ito3

  • 1Frontier Research Laboratories, Daiichi Sankyo Co., Shinagawa-ku, Tokyo 140-3710, Japan.

Drug Discovery Today
|May 6, 2014
PubMed
Summary

Successful clinical trials for interleukin-17 (IL-17) inhibitors in psoriasis support developing new therapies for autoimmune diseases. Targeting the IL-17 pathway, particularly the RORγt regulator in Th17 cells, offers promising therapeutic strategies.

More Related Videos

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

1.1K
Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

3.2K

Related Experiment Videos

Last Updated: Apr 30, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

33.7K
Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

1.1K
Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

3.2K

Area of Science:

  • Immunology
  • Pharmacology
  • Autoimmune Diseases

Background:

  • Interleukin-17 (IL-17) pathway is implicated in chronic inflammation and autoimmune disorders.
  • Recent clinical trial successes with IL-17 antibodies for psoriasis validate this pathway as a therapeutic target.

Purpose of the Study:

  • To review strategies for inhibiting the IL-17 pathway.
  • To explore the development of orally available small molecules targeting IL-17 production or signaling.
  • To emphasize retinoic-acid-related orphan nuclear receptor RORγt as a key therapeutic target.

Main Methods:

  • Review of recent clinical trial data for IL-17 inhibitors.
  • Analysis of drug discovery approaches for small molecule inhibitors.
  • Focus on the role of RORγt in Th17 cell regulation.

Main Results:

  • Antibodies targeting IL-17 or its receptor show success in late-stage clinical trials for psoriasis.
  • This validates the IL-17 pathway as a therapeutic target for chronic inflammation and autoimmunity.
  • RORγt emerges as a master regulator of Th17 cells, presenting a promising target for drug development.

Conclusions:

  • Inhibitors of the IL-17 pathway represent a new therapeutic modality for autoimmune disorders.
  • Drug discovery efforts are encouraged for orally available small molecules targeting IL-17 production or signaling.
  • Inhibiting RORγt is a key strategy for treating multiple autoimmune diseases by modulating Th17 cell activity.